CGC
Fiscal year ends March Quarters are offset from the calendar — Q1 is Apr–Jun

Canopy Growth Corporation is a cannabis company that produces, distributes, and sells medical and adult-use cannabis products in Canada, Europe, and Australia. Incorporated in 2009, the company operates under a portfolio of distinct brands, including Tweed, 7ACRES, Maitri, HiWay, Twd., Wana, Claybourne, DOJA, DeeLish, MTL Cannabis, LowKey, R’belle, and Deep Space for the adult-use market, and Spectrum Therapeutics and Canopy Medical for medical patients. The company supplies products in various formats, such as dried flower, pre-rolled joints, oils, softgel capsules, edibles, and vapes. Canopy Growth also manufactures herbal vaporizer devices through its subsidiary Storz & Bickel. The company serves medical patients through a network of clinics operating under the Apollo, Canada House, and Abba Medix banners. It holds a non-controlling, non-voting interest in Canopy USA, which participates in the sale of cannabis products in the United States. Canopy Growth supplies medical cannabis to markets in Germany, Poland, and Australia, and has expanded supply into the United Kingdom. The company utilizes EU-GMP certified facilities for production and distribution.

Summarised from the company's own disclosures, fiscal year ended Jun 2026

Industry Packaged Foods Homepage canopygrowth.com
Sector Consumer Defensive IR page canopygrowth.com/investors
Tags
medical cannabis, adult-use cannabis, vaporizer devices, cannabis cultivation, edibles, dried flower, pre-rolled joints, cannabis oils, softgel capsules, vapes, Tweed, 7ACRES, Maitri, HiWay, Twd., Wana, Claybourne, DOJA, DeeLish, MTL Cannabis, LowKey, R’belle, Deep Space, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Storz & Bickel GmbH, Canopy USA, Apollo, Canada House, Abba Medix, MTL Cannabis Corp.
Press page canopygrowth.com/news

Metrics

Valuation  
Market cap $ 379.409M
Market cap (USD) $ 379.409M
P/E -1.63
PEG —
P/BV 0.83
P/S 1.75
P/OCF -8.43
P/FCF -7.78
Dividend yield —
Turnover / mcap —
Returns  
ROE -44.4%
ROI -28.2%
ROIC -13.0%
Profit margin -92.4%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 37.8%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 19
Quality score -66.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Revenue 284.603M 268.995M 297.146M 402.904M 520.325M 546.649M 398.772M 226.341M 77.948M 39.895M
Net profit -262.908M -598.115M -657.269M -3.278B -302.181M -1.745B -1.321B -685.438M -54.134M -7.572M
Free cash flow -69.139M -176.563M -285.399M -566.763M -582.495M -630.231M -1.478B -1.165B -257.543M -56.484M

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Share price 1.32 1.27 11.76 2.38 17.46 41.82 — — — —
Price performance 12m 0.04 -0.89 3.93 -0.87 -0.57 — — — — —

Filed figures

Figure Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Balance sheet detail
Trade receivables (CAD) — — 61.8M 51.2M 67.1M 78.1M 66.8M 44.9M 47.5M 31.2M
↳ YoY growth -17.2% +31.2% +16.3% -14.4% -32.7% +5.7% -34.2%
↳ 5y CAGR -6.2% -1.5% -14.2%
Borrowings, current (CAD) — — 104M 16.4M 9.83M 9.3M 557M 104M 4.26M 16.2M
Borrowings, non-current (CAD) — — 842M 449M 1.57B 1.49B 750M 493M 300M 217M
Lease liabilities (CAD) — — — 160M 136M 139M 109M 70.8M 44.3M 45.4M
Cash and deposits (CAD) — — 2.48B 1.3B 1.15B 776M 677M 170M 114M 365M
Intangible assets (CAD) — — 558M 476M 308M 253M 189M 104M 87.2M 92.4M
Right-of-use assets (CAD) — — — 73.4M 47.5M 39.6M 20.7M 7.15M 4.56M 20.2M
Net debt (borrowings + leases - cash) (CAD) — — -1.53B -677M 565M 864M 739M 498M 235M -86M
Cash flow detail
Operating cash flow (CAD) — -81.5M -535M -773M -466M -546M -558M -282M -166M -63.8M
Purchases of property, plant and equipment (CAD) — -176M -644M -705M -165M -36.7M -9.22M -3.45M -10.8M -5.33M
Purchases of intangible assets (CAD) — -2.13M -74.4M -17M -9.64M -11.4M -1.34M -547,000 -467,000 -620,000
Change in receivables (cash effect) (CAD) — -15.7M -67.7M 21M -12M 3.74M -9.91M -3.75M -4.49M 25.7M
Change in inventories (cash effect) (CAD) — -21.8M -145M -177M 17.2M 173M 55.6M 1.03M -17.7M 3.71M
Change in payables (cash effect) (CAD) — 27.1M 69.5M -20.8M -9.63M -35.8M 17.6M 9.12M -15.5M -4.35M
Interest paid (cash effect) (CAD) — — — -25.5M -25.6M -119M -132M -98.1M -64.9M -29M
Income taxes paid (cash effect) (CAD) — 0.00 -502,000 -5.46M -22.8M -2.64M -1.18M -2.08M -783,000 -144,000
Share-based compensation (CAD) — 49.1M 273M 320M 91.1M 47.5M 31.2M 14.2M -4.21M 4.27M
Operating cash flow before change in receivables (CAD) — -65.8M -467M -794M -454M -550M -548M -278M -161M -89.5M
Free cash flow (OCF - PPE - intangibles) (CAD) — -260M -1.25B -1.49B -640M -594M -568M -286M -177M -69.8M
Income detail
Research and development expense (CAD) 810,000 1.45M 15.2M 61.8M 57.6M 32.3M 21.7M 4.61M 2.74M 2.61M
↳ 5y CAGR +109.1% +71.8% -21.3% -46.4% -46.1%
Total comprehensive income (CAD) — -27.7M -719M -1.16B -1.93B -345M -3.25B -689M -585M -253M
Comprehensive income to owners (CAD) — -48M -743M -1.09B -2B -326M -3.22B -671M -585M -253M
Reported Jun 28, 2018 Jun 1, 2020 Jun 1, 2020 May 31, 2022 May 31, 2022 May 31, 2022 Jun 22, 2023 May 30, 2024 May 30, 2025 Jun 15, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Net revenue growth of 30% in Cannabis segment

18% growth in Canada medical cannabis revenue and 17% growth in Canada adult-use cannabis revenue

Company strengthens end-to-end EU GMP supply chain to facilitate further international growth

SMITHS FALLS, ON, November 6, 2026 - Canopy Growth Corporation (“Canopy Growth”, “our”, “we” or the “Company”) (TSX: WEED) (Nasdaq: CGC), a leading global company committed to bettering lives through cannabis, today announced its financial results for the three months ended September 30, 2026 ("Q2 FY2027"). All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.

“We have made tremendous progress on our international strategy. Our international business delivered 141% net revenue growth in the second quarter of fiscal year 2027 driven by strong medical cannabis sales in Germany and Poland. We entered the U.K. market, added to our German leadership team, broadened our product portfolio in Australia and expanded our end-to-end EU GMP-certified supply chain through the certification of our Smiths Falls facility.

SMITHS FALLS, ON – October 26, 2026 – Canopy Growth Corporation (“Canopy Growth”, “our”, “we” or the “Company”) (TSX: WEED) (Nasdaq: CGC), a leading global company committed to bettering lives through cannabis, today announced the voting results from its annual general and special meeting of shareholders convened on September 25, 2026, and adjourned to and reconvened on October 23, 2026 (the “Meeting”).

A total of 154,837,897 common shares of the Company (the “Shares”), representing 36.60% of the issued and outstanding Shares, were voted in connection with the Meeting by the Company’s shareholders (the “Shareholders”).

All of the matters put forward before the Shareholders for consideration and approval, as set out in the Company’s definitive proxy statement dated August 7, 2026 (the “Proxy Statement”), were approved by the requisite number of votes cast at the Meeting, as further detailed below.

Election of Directors

Each of the directors of the Company’s board of directors (the “Board”) listed as a nominee in the Proxy Statement were elected at the Meeting to serve as a director of the Company until the Company’s next annual shareholders meeting or until his or her successor is duly elected or appointed.

The detailed results of the vote for the election of directors held at the Meeting are set out below:

| Name Of Nominee | Votes cast FOR | % Votes cast FOR | Votes AGAINST | % Votes AGAINST |

| David Lazzarato | 78,059,502 | 87.16% | 11,499,873 | 12.84% |

| Theresa Yanofsky | 76,020,874 | 84.88% | 13,538,500 | 15.12% |

| Luc Mongeau | 79,871,589 | 89.18% | 9,687,785 | 10.82% |

| Shan Atkins | 79,773,303 | 89.07% | 9,786,072 | 10.93% |

| Joseph Bayern | 79,713,027 | 89.01% | 9,846,347 | 10.99% |

Appointment of Auditors

Shareholders also approved the appointment of MNP LLP (“MNP”) as the Company’s auditor and independent registered public accounting firm for the fiscal year ending March 31, 2027, and authorized the Board or any responsible committee thereof to fix MNP’s remuneration

Share Consolidation

Shareholders adopted a special resolution authorizing an amendment to the articles of the Company to, among other things, consolidate the Company’s issued and outstanding Shares and exchangeable shares of the Company on the basis of a ratio to be determined by the board of directors of the Company (the “Board”), in its sole discretion, within a range of one post-consolidation share for every five to fifteen outstanding pre-consolidation shares, as more particularly described in the Proxy Statement.

The share consolidation will only be implemented, if at all, upon a determination by the Board that it is in the best interest of the Company and its Shareholders. If the Board does not implement the share consolidation within 12 months of the date of the Meeting, the authority granted to the Board will lapse and be of no further force or effect.

Advance Notice By-Law

Shareholders adopted an ordinary resolution ratifying and approving the adoption of the By-Law No. 2 of the Company, which establishes advance notice and certain other requirements for Shareholders proposing director nominations for Shareholder meetings of the Company, as more particularly described in the Proxy Statement.

Renewal of Omnibus Incentive Plan

Shareholders adopted an ordinary resolution authorizing and approving all unallocated entitlements under the Company’s Omnibus Incentive Plan, as more particularly described in the Proxy Statement.

Advisory Vote on the Compensation of the Company’s Named Executive Officers

Shareholders also adopted an advisory (non-binding) resolution approving the compensation of the Company’s named executive officers (the “NEOs”), as more particularly described in the Proxy Statement.

Advisory Vote on the Frequency of Future Votes on the Compensation of the NEOs

In the advisory (non-binding) vote on the frequency of future advisory (non-binding) votes on the compensation of the Company’s NEOs, the option to hold a vote every one year received the greatest number of votes from the Shareholders.

On September 25, 2026, Canopy Growth Corporation (“Canopy Growth”) convened and adjourned to, and reconvened on, October 23, 2026, its 2026 Annual General and Special Meeting of Shareholders (the “Annual Meeting”). A total of 423,037,675 common shares of Canopy Growth (“Shares”) were entitled to vote as of July 31, 2026, the record date for the Annual Meeting. There were 154,837,897 Shares represented at the Annual Meeting, at which Canopy Growth’s shareholders were asked to vote on seven proposals, each of which is described in more detail in Canopy Growth’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on August 7, 2026 (the “Proxy Statement”). Set forth below are the matters acted upon by Canopy Growth’s shareholders, and the final voting results of each such proposal.

Proposal No. 1: Election of Director Nominees.

Prompts

Canopy Growth Corporation (ticker CGC), listed in United States.

ETFs Holding Canopy Growth Corporation

ETF Weight in ETF Shares Market value As of
YOLO 0.73% 381,715 $ 202.843K Nov 17, 2026
SYZ 0.14% 100,981 $ 95.932K Jun 30, 2026
DFIC 0.00% 81,350 $ 46.773K Nov 12, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
CGC canonical Common share — US nasdaq 0.90 USD 2026-09-30
WEED Common share — CA tsx — —